Literature DB >> 6172170

Gamma (immune) interferon production by leukocytes from a patient with a TG cell proliferative disease.

J J Hooks, B F Haynes, B Detrick-Hooks, L F Diehl, T L Gerrard, A S Fauci.   

Abstract

We report a patient with a disease characterized by proliferation of T cells with Fc receptors for IgG (TG). However, unlike lymphoid cells from normal individuals or from patients with other lymphoid malignancies, the patient's lymphocytes spontaneously produced gamma interferon (IFN-gamma) in vitro. The peripheral lymphocytes consisted of 95% TG cells, which exhibited the morphological characteristics of T-cell chronic lymphocytic leukemia (CLL) and were normal on cytochemical and chromosome analysis. The majority of TG cells were OKT3+, OKT8+, and OKT4-, 3A1-. These cells failed to express suppressor cell activity and displayed depressed levels of natural killer activity, but mediated antibody-dependent cell-mediated cytotoxicity. The spontaneous production of IFN-gamma by human peripheral lymphoid cells as demonstrated in this study may serve as a probe for studying the relationship between IFN-gamma and the proliferation of human T-cell subsets.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6172170

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Increased activity of oligo-2',5'-adenylate synthetase in Down's syndrome and epilepsy.

Authors:  N Fujii; K Oguma; M Fujii; R Fukatsu; N Takahata; M Kitabatake
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

2.  An unusual variant of T-CLL: evidence for the existence of a hitherto unrecognized T cell subset.

Authors:  V E Moss; F Miedema; E Matutes; F Terpstra; A Brownell; M Brozovic; D Catovsky
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

Review 3.  Abnormal expansions of granular lymphocytes: reactive lymphocytosis or chronic leukemia? Case report and literature review.

Authors:  G Gastl; H Rumpold; D Kraft; C Gattringer; G Schuler; R Margreiter; F Schmalzl; C Huber
Journal:  Blut       Date:  1986-02

4.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells.

Authors:  M Tsudo; C K Goldman; K F Bongiovanni; W C Chan; E F Winton; M Yagita; E A Grimm; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

5.  Inverse relationship between constitutive gamma interferon production and human T-cell lymphoma/leukemia virus expression in cultured T lymphocytes.

Authors:  J L Moore; B J Poiesz; K W Zamkoff; S A Merl; S Hanna; A F Gazdar; R L Comis
Journal:  J Virol       Date:  1985-02       Impact factor: 5.103

6.  Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome.

Authors:  T H Bacon; F Ozbakir; C A Elms; A M Denman
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

7.  Classification of patients with T-cell chronic lymphocytic leukemia and expansions of granular lymphocytes: heterogeneity of Italian cases by a multiparameter analysis.

Authors:  F Pandolfi; F Mandelli; G Semenzato; A Ranucci; F Aiuti
Journal:  J Clin Immunol       Date:  1984-05       Impact factor: 8.317

8.  A lymphoproliferative disorder of granular lymphocytes with a novel phenotype and suppressor function.

Authors:  A Landay; M C Poon; L T Clement; C E Grossi
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

9.  Interferon gamma production by human intestinal mucosal mononuclear cells. Decreased levels in inflammatory bowel disease.

Authors:  B Y Lieberman; C Fiocchi; K R Youngman; W K Sapatnekar; M R Proffitt
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

10.  T gamma lymphocytosis is clinically non-progressive but immunologically heterogeneous.

Authors:  F Miedema; F G Terpstra; J W Smit; J P van der Veen; C J Melief
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.